Eric B. Lev serves as Non-Executive Director of the Company. He was initially designated as director effective July 15, 2019 by Ampersand as holder of Series A Preferred Stock, and thereby appointed and elected to the Board and was re-designated as director by Ampersand as holder of Series B Preferred Stock, and thereby re-appointed and re-elected to the Board effective January 15, 2020. On January 22, 2020, the Company named Mr. Lev to the Nominating Committee and as Chair to the Regulatory Compliance Committee. Mr. Lev has more than 17 years of experience in life science investing. Since 2013, Mr. Lev has been a partner at Ampersand Capital Partners, a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector and an entity affiliated with Ampersand. From 2005 to 2013, Mr. Lev was a principal at Water Street Healthcare Partners, and served before then as Group Manager, Strategy & Business Development at Beckman Coulter from 2004 to 2005. Mr. Lev also previously served as an associate on the healthcare/life sciences team at One Equity Partners and began his career as an analyst in the investment banking division of Lehman Brothers. He currently serves on the boards of directors of private companies within the pharmaceutical services market such as Nexelis and New England Peptide. He previously served on the boards of directors of private companies within the clinical laboratory services market such as Genoptix, Inc., PLUS Diagnostics, and ConVerge Diagnostic Services LLC. Mr. Lev holds a B.A. from Northwestern University and a M.B.A from the University of Chicago.
Eric Lev is 44, he's been the Non-Executive Director of Interpace Biosciences Inc since 2019. There are 8 older and 1 younger executives at Interpace Biosciences Inc. The oldest executive at Interpace Biosciences Inc is Stephen Sullivan, 73, who is the Chairman of the Board.
Eric's mailing address filed with the SEC is C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY, PARSIPPANY, NJ, 07054.
Over the last 9 years, insiders at Interpace Biosciences Inc have traded over $0 worth of Interpace Biosciences Inc stock and bought 94,105 units worth $353,961 . The most active insiders traders include Peter Kamin, Nat Krishnamurti és Graham G Miao. On average, Interpace Biosciences Inc executives and independent directors trade stock every 99 days with the average trade being worth of $48,561. The most recent stock trade was executed by Thomas W. Burnell on 21 May 2021, trading 10,855 units of IDXG stock currently worth $94,221.
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Interpace Biosciences Inc executives and other stock owners filed with the SEC include: